|
|
Post by akemp3000 on Aug 9, 2023 5:10:21 GMT -5
What an exciting time for Mannkind Corp. Thank you prcgorman and agedhippie for the thorough explanation of the INHALE-1 study for Afrezza use in pediatrics. It has the potential to once and for all replace Afrezza's "Non-inferior" tag with a "Superior" tag plus remove the safety concern that exists with all doctors who have been taught that prescribing insulin must always be the last resort. Add to this the INHALE-3 study that has the potential to replace current Type 1 diabetes treatments with a combination of Afrezza, Tresiba and Dexcom which would then only require one shot per week. It appears we are nearing a possible mic drop moment in the history of diabetes. If so, it should be called a MIKE DROP MOMENT!
|
|
|
|
Post by prcgorman2 on Aug 9, 2023 6:39:51 GMT -5
My wife has a cousin whose T1 father passed away from COVID-19, and who has a T1 son. She is the only person I have ever met who knew about Afrezza before I told them about it. She investigated the pediatric trial opportunity which didn’t materialize for years thanks to Sanofi. I don’t know how much she or her son would care about Afrezza now (he’s a teenager) but I do know there will be lots of other moms who will care a lot to have Afrezza as an option for their young T1s. Mic drop or not, this has been a long time coming and I’m very glad that MannKind, including Dr. Kendall I assume, did a good job of designing the trial and many young people should benefit from it, and I am grateful.
|
|
|
|
Post by Thundersnow on Aug 9, 2023 11:02:09 GMT -5
What an exciting time for Mannkind Corp. Thank you prcgorman and agedhippie for the thorough explanation of the INHALE-1 study for Afrezza use in pediatrics. It has the potential to once and for all replace Afrezza's "Non-inferior" tag with a "Superior" tag plus remove the safety concern that exists with all doctors who have been taught that prescribing insulin must always be the last resort. Add to this the INHALE-3 study that has the potential to replace current Type 1 diabetes treatments with a combination of Afrezza, Tresiba and Dexcom which would then only require one shot per week. It appears we are nearing a possible mic drop moment in the history of diabetes. If so, it should be called a MIKE DROP MOMENT! Let's not put the cart before the horse. The interim analysis will be HUGE. There are too many variables that could happen in October. Let's all be careful with our optimism. |
|
|
|
Post by ktim on Aug 9, 2023 11:09:06 GMT -5
What an exciting time for Mannkind Corp. Thank you prcgorman and agedhippie for the thorough explanation of the INHALE-1 study for Afrezza use in pediatrics. It has the potential to once and for all replace Afrezza's "Non-inferior" tag with a "Superior" tag plus remove the safety concern that exists with all doctors who have been taught that prescribing insulin must always be the last resort. Add to this the INHALE-3 study that has the potential to replace current Type 1 diabetes treatments with a combination of Afrezza, Tresiba and Dexcom which would then only require one shot per week. It appears we are nearing a possible mic drop moment in the history of diabetes. If so, it should be called a MIKE DROP MOMENT! Let's not put the cart before the horse. The interim analysis will be HUGE. There are too many variables that could happen in October. Let's all be careful with our optimism. Unbridled optimism has long run rampant. The cart was long ago put so far ahead of the horse it was down the road in a different county. Finally the horse is catching up. |
|
|
|
Post by Chris-C on Aug 9, 2023 12:56:51 GMT -5
Let's not put the cart before the horse. The interim analysis will be HUGE. There are too many variables that could happen in October. Let's all be careful with our optimism. Unbridled optimism has long run rampant. The cart was long ago put so far ahead of the horse it was down the road in a different county. Finally the horse is catching up. The admonitions about unbridled optimism, which at their core are wise, caused me to reflect on what "unbridled optimism" actually is? Is it mortgaging your home or borrowing $$ from a 401K (as many in the U.S. are doing now to maintain lifestyles above their means) to bet on a stock? It occurred to me that as an investor who has had a stake in MNKD for well over 10 years, my continuing to buy MNKD shares in the face of one obstacle or disappointment after another, especially knowing that my investment was underwater, might be termed unbridled optimism. Yet I persisted. My first error was to underestimate the adoption of Afrezza. I didn't fully appreciate the knowable headwinds and it never occurred to me that the company had not done its homework to fully understand the dosing and reimbursement challenges or the prescriber resistance. Fast forward, and finally Afrezza is getting some traction. In the meantime, MNKD has wisely morphed into an endocrine and pulmonary pharma company. Its royalties from Tyvaso DPI are a major driver of revenue, and it has other drugs in the pipeline. Of course, with the exception of meme stocks, what matters to the street in most cases is execution and performance. With all that has happened, long term investors in this company will not be surprised at any negative development. But if Martine Rothblatts unfettered public ebullience about Tyvaso is even partially right, there is a basis for having some optimism about continued momentum in SP. Warren Buffett advises to know what you own and be patient. That requires optimism and confidence. Sometimes I think that the experience and dashed expectations of this company create a feeling where no positive development should be trusted, since a shoe filled with bad news is soon to fall. Personally, I've never felt better about this investment than I do know. Being above water feels really good. But it hasn't changed my behavior, as I still purchase shares because I continue to believe in the company and its products. But now I also have confidence in the leadership based on its performance (and MC's leadership). So after well over a decade, I'll continue to watch and be optimistic, but I won't be managing my finances based on my unrealized gains. GLTAL Chris - C |
|
|
|
Post by ktim on Aug 9, 2023 14:47:13 GMT -5
It wasn't an admonition to anyone... just a statement of fact, lol.
I'm an investor in MNKD dating back to right before the first CRL, so definitely know the roller coaster. I'm also lucky enough to have done some trading (always long) along the way, yielding overall a positive return and outlook on the whole journey. Some I know are still harboring losses.
As for shoes to drop, that may be still joked about here, but I think most realize we are in so much better position. We have the cash. The dilution still coming is sizable but certainly not an unknown shoe filling and has been priced in (IMHO). Afrezza has almost completely been written off as a growth propellant by investors at this point (again IMO)... i.e. I think that has been removed as source of much negative reaction. If the new trials are lackluster as previous ones, that is what is priced in.
Volatility in stock price is to be expected. Dropping shoes of bad news, not so much.
Though I suppose fire at a plant producing one of our clinical stage APIs gave fodder for jokes about a MNKD curse. To be on the safe side and put the hex to rest once and for all, perhaps Mike should make a sacrifice of bulk spray dried blood to the biotech god IBBy, lol
|
|
|
|
Post by Chris-C on Aug 9, 2023 15:19:10 GMT -5
It wasn't an admonition to anyone... just a statement of fact, lol. I'm an investor in MNKD dating back to right before the first CRL, so definitely know the roller coaster. I'm also lucky enough to have done some trading (always long) along the way, yielding overall a positive return and outlook on the whole journey. Some I know are still harboring losses. As for shoes to drop, that may be still joked about here, but I think most realize we are in so much better position. We have the cash. The dilution still coming is sizable but certainly not an unknown shoe filling and has been priced in (IMHO). Afrezza has almost completely been written off as a growth propellant by investors at this point (again IMO)... i.e. I think that has been removed as source of much negative reaction. If the new trials are lackluster as previous ones, that is what is priced in. Volatility in stock price is to be expected. Dropping shoes of bad news, not so much. Though I suppose fire at a plant producing one of our clinical stage APIs gave fodder for jokes about a MNKD curse. To be on the safe side and put the hex to rest once and for all, perhaps Mike should make a sacrifice of bulk spray dried blood to the biotech god IBBy, lol Yes, I've heard that the IBBy biotech god is worthy of fear, and it never hurts to curry favor with the powerful and vengeful.  That said, I apologize for any suggestion that you were scolding anyone as that was not the intent, since I agreed that it's unwise to get too far ahead of one's skis. Perhaps the words comment or advice would have been more suitable and less pejorative in interpretation. Good luck to us all! Chris-C |
|
|
|
Post by akemp3000 on Aug 9, 2023 15:34:32 GMT -5
Regardless of bridled or unbridled optimism, carts and horses, shoes dropping, roller coasters, past history or getting ahead of skis, I remain convinced it "appears" we could be nearing a possible MIKE DROP MOMENT. I just wanted to point out one possible 60k foot view while the daily debates continue  |
|
|
|
Post by Chris-C on Aug 9, 2023 16:03:15 GMT -5
Regardless of bridled or unbridled optimism, carts and horses, shoes dropping, roller coasters, past history or getting ahead of skis, I remain convinced it "appears" we could be nearing a possible MIKE DROP MOMENT. I just wanted to point out one possible 60k foot view while the daily debates continue Noted. My sense is that the existing debate is largely a matter of how far and how quickly the SP advances. I sense widespread agreement that the company is headed in a positive direction. Would you define "mic drop moment" as the point at which the secondary rockets ignite to propel the SP into double digits? |
|
|
|
Post by cretin11 on Aug 9, 2023 16:10:08 GMT -5
Getting back to price levels around time of Afrezza approval - now that would be a mic drop moment!
|
|
|
|
Post by akemp3000 on Aug 9, 2023 16:43:05 GMT -5
Great question as to when the mic drop moment might actually occur. There seems to be several in sight; one when Afrezza is approved for pediatrics, one when Afrezza is labeled "Superior" and one when the Afrezza, Tresiba, Dexcom combination is announced as equal or better quality of life solutions for T1s. "IF" all three occur, it's no longer a mic drop moment, it's a MIKE SPIKE dance in the end zone ...though Cretin's answer is great. |
|
|
|
Post by mymann on Aug 22, 2023 12:04:52 GMT -5
Mike drop moment can't come seem enough. Drop that dead beat.
|
|
|
|
Post by runner on Aug 22, 2023 13:14:39 GMT -5
The last two weeks, I’ve only seen a price drop, not a mic drop. I would love to see and hear a mic drop between now and the end of the month.
|
|
|
|
Post by cretin11 on Aug 22, 2023 13:18:21 GMT -5
Agree with the last two posts. We’ve seen the price drop, now would be nice to have the mic drop and/or the mike drop. 🙏🏽
|
|
|
|
Post by prcgorman2 on Aug 22, 2023 15:01:34 GMT -5
So people don't forget the reason for the thread, its about an anticipated moment in the future as in next year, or even the year after depending upon how fast the trial of Afrezza inhalable insulin for pediatric use can be completed, the data analyzed, and then reported. It wasn't about a "microphone drop" moment to dramatically increase share price in the near term.
|
|
That said, I apologize for any suggestion that you were scolding anyone as that was not the intent, since I agreed that it's unwise to get too far ahead of one's skis. Perhaps the words comment or advice would have been more suitable and less pejorative in interpretation. 
